Related Experiment Video
Updated: Jan 14, 2026
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
Generation and functional evaluation of bispecific T cell engaging antibodies
Antonio Tapia-Galisteo1, Rodrigo Lázaro-Gorines1, Luis Álvarez-Vallina1
1Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
T cell engagers (TCE) are bispecific antibodies that bridge T cells and tumors for potent cancer cell killing. This study details protocols for designing, generating, and validating both IgG-like and non-IgG-like TCE formats.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- T cell engagers (TCE) are bispecific antibodies targeting tumor antigens and CD3 to activate T cells.
- TCEs induce potent, TCR-independent cytotoxic responses, revolutionizing hematological cancer treatment.
- TCEs exist in IgG-like and non-IgG-like formats, each with distinct structural and pharmacokinetic properties.
Purpose of the Study:
- To provide detailed protocols for the design, generation, and validation of both non-IgG-like and IgG-like TCEs.
- To outline methods for recombinant production and comprehensive characterization of TCE constructs.
- To facilitate the development and application of novel TCE-based immunotherapies.
Main Methods:
- Construct generation and antibody expression in mammalian systems.
- Purification of TCEs using chromatography.
- Structural and functional characterization via biophysical, in vitro, and in vivo studies.
Main Results:
- Established protocols cover the complete workflow from TCE design to characterization.
- Demonstrated successful generation and validation of both IgG-like and non-IgG-like TCE formats.
- Provided a comprehensive methodology for producing and analyzing TCEs for therapeutic development.
Conclusions:
- The presented protocols offer a robust framework for developing and producing diverse T cell engager formats.
- These detailed methods will aid researchers in advancing TCE-based immunotherapies for various cancers.
- Standardized protocols are crucial for the reproducible manufacturing and clinical translation of TCE therapeutics.
